Glaukos Announces Closing of Its Initial Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS) today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the public of $18.00 per share, which included an additional 900,000 shares pursuant to the exercise in full of the underwriters’ option to purchase additional shares. Total net proceeds to Glaukos from the offering, including proceeds from the option exercise, after deducting underwriting discounts and commissions and estimated offering expenses, were approximately $112.3 million.

J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. acted as joint book-running managers for the offering. William Blair and Cantor Fitzgerald & Co. acted as co-managers for the offering.

A registration statement relating to these securities was filed with the Securities and Exchange Commission and has been declared effective. The offering was made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Phone: (866) 803-9204; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com; or Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or email at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos launched iStent Trabecular Micro-Bypass Stent, the industry's first Micro-Invasive Glaucoma Surgery (MIGS) device, in the United States in 2012. The company is based in Laguna Hills, CA.